Peter Greenleaf
And finally this week there is news from regenerative medicine company Histogenics who has appointed Peter Greenleaf as its new CEO.
Greenleaf most recently served as President of MedImmune, the biologics arm of AstraZeneca, and before this in his twenty year career he has held senior roles at Centocor, Boehringer Mannheim and U.S. Healthcare.
“Peter’s expertise in growing smaller biotech companies into industry leaders will be critical as we work to move NeoCart [a personalized hyaline-like cartilage tissue implant for patients using their own cells] through pivotal trials and ultimately toward launch and commercialization,” said Histogenics Chairman Garheng Kong.
